Six strategies to reinvigorate the doctor-patient bedside encounter
Peer-Reviewed Publication
Updates every hour. Last Updated: 13-Jan-2026 21:11 ET (14-Jan-2026 02:11 GMT/UTC)
Today’s doctor visits look and feel a lot different than they did even just a couple decades ago.
Rushed physicians and medical trainees are spending less time with patients, leading to diagnostic errors, poor patient outcomes and increased costs in health care. The influx of AI and other new technology has led to a decline in modern medical trainees’ fundamental bedside skills and a weakening of the doctor-patient relationship. There is a lack of empathy and an increase in physician stress and burnout. The list goes on.
To help reverse these trends, a new report from Northwestern University and the University of Alabama at Birmingham provides six practical strategies to reinvigorate a waning culture of bedside medicine in this new health care environment. The suggestions give clinicians and medical educators guidance on how to better teach and practice important bedside clinical skills, such as the physical exam.
Research Professor Jacob Segil has created a redesigned surgical instrument called the CAP-LIFT cannula. The device was recently launched in October, and within the first few weeks used in over 100 successful surgeries.
A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner.
Published in Blood Advances, the research is the first longitudinal, single-cell, multi-omic study of cilta-cel in multiple myeloma. Cilta-cel (ciltacabtagene autoleucel) is a type of CAR T cell therapy used to treat relapsed or refractory multiple myeloma. It works by using a patient's own T cells, which are genetically engineered in a lab to target and kill cancer cells that have B cell maturation antigen (BCMA) on their surface. The modified T cells are then infused back into the patient as a one-time treatment to fight the cancer.
Cervical cancer, one of the most common cancers in women, is often treated with surgery, radiation, or chemotherapy, which can affect fertility and quality of life. Researchers at Chiba University have developed a new nasal therapeutic vaccine as a non-invasive treatment option. In animal studies, the vaccine produced strong and lasting immune responses against cervical tumors. If proven effective in humans, it could provide women with a safer, fertility-preserving alternative to current cancer treatments.